Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy of Auvelity from entering the U.S. market until at least 2038.

In what one analyst called a “unique situation,” the company stopped dosing patients on the recommendation of trial monitors, ...

From preclinical research to regulatory approval and clinical adoption, diagnostic testing underpins every stage of ADC ...